30-Apr-2021 - Vetter Pharma International GmbH

Vetter and Rentschler Biopharma Further Strengthen their Strategic Alliance

Rentschler Biopharma and Vetter announced that their strategic collaboration has taken key steps forward. The companies have further strengthened the established framework for their alliance and set up a governance structure, as well as implemented guidelines for their joint approach across functions. In parallel to starting their first joint client projects, they are also working closely on existing projects and related topics.

The collaboration was initiated in mid-2020, with the intent to create long-term value through the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster. Together, the two CDMOs are mutually enhancing their services by offering complementary skills and experience along the biopharmaceutical value chain. Today’s announcement marks a milestone in the development of this important collaboration.

The established framework consists of an overall collaboration agreement that regulates the intended contributions of both parties to ultimately generate added value for clients and patients around the world. Further operational agreements and guidelines between various departments including Quality, Development Service and Logistics have been implemented. These cover key standards for joint approaches as well as core inputs and processes across both organizations to align interfaces and optimize services for the client’s convenience and long-term planning.

“The formation of the mutual agreements and alignment on a client approach were foundational steps that both Vetter and Rentschler Biopharma identified early in our exploration of this strategic alliance,” stated Vetter Managing Director Peter Soelkner. “We look forward to the new progress that this step will facilitate.”

The close alignment of departments also includes the companies’ global business development teams. The two organizations have now clearly defined the target markets for their collaboration, focusing on Europe, US and the Asia-Pacific, as well as emerging markets. The teams are working closely together to approach clients who may derive value from the complementary skills provided by both CDMOs. Vetter and Rentschler Biopharma have already successfully initiated their first joint client projects, and additional projects are in discussion.

“We are very interested to see how the experience gained in these initial projects will further enhance our strategic alliance,” noted Dr. Frank Mathias, CEO of Rentschler Biopharma. “These client engagements will provide valuable insights for our teams to leverage in refining the alignment of our processes and approaches.”

As their collaboration matures, both companies will still independently address and service current and new clients while they pursue further cooperative integration of their services and expertise in todays’ rapidly evolving global healthcare environment. Both organizations remain committed to simplifying and accelerating the development of promising new therapies for patients with serious and rare diseases and will continue to pursue a range of strategic initiatives designed to support this goal globally.

More about Vetter
  • News

    Vetter establishes office in China to better serve the needs of its growing customer base worldwide

    Vetter announced the opening of a new business entity in Shanghai, China. The new office, now its fourth in the Asia Pacific (APAC) region, will help increase the visibility of Vetter’s presence in China and underlines its importance as an important strategic market to Vetter. Thus, the off ... more

    Vetter Works Towards a Sustainable Energy Supply

    Vetter has reached another important milestone regarding sustainability. Beginning immediately, all German sites of the company will be supplied with only CO2 neutral energy from certified renewable energy sources. This action underlines the CDMO’s commitment to climate and environmental pr ... more

    Vetter expands its footprint in Asia Pacific region

    Vetter announced the official opening of a new branch office in South Korea. The newoffice in Songdo is located within the biologics cluster which is often referred to as a ‘sweet spot’ by the industry as it houses numerous prominent biopharmaceutical companies and service providers. Streng ... more

  • Companies

    Vetter Pharma International GmbH

    Vetter is an independent international specialist in the production of aseptically pre-filled injection systems, cartridges and vials. For more than 25 years, the name of Vetter has stood for quality, innovation and strategic partnerships. Our customized products and processes have been app ... more

More about Rentschler
  • News

    Rentschler Biopharma entry into cell and gene therapy

    The Cell and Gene Therapy Catapult (CGT Catapult), an independent centre of excellence in innovation advancing the UK's cell and gene therapy industry, and Rentschler Biopharma SE have announced that Rentschler Biopharma will establish their manufacturing capability in Advanced Therapy Medi ... more

    Rentschler Biotechnologie GmbH transforms into European corporation

    Rentschler Biotechnologie GmbH announced that the Company has successfully transitioned into a European corporation (SE) with entry into the German commercial register on October 1, 2017. The Company is operating as Rentschler Biopharma SE with immediate effect. There will be no operational ... more

    Rentschler Biotechnologie and Rentschler Fill Solutions Announce Strategic Partnership

    Rentschler Biotechnologie GmbH and Rentschler Fill Solutions GmbH announced a strategic partnership to provide new fill and finish facilities and one-stop solutions for biopharmaceutical products to meet the needs of Rentschler Biotechnologie’s clients. Under the terms of the agreement, Ren ... more

  • Companies

    Rentschler Biotechnologie GmbH

    Rentschler is a biopharmaceutical contract manufacturer with over 35 years proven track record. As an independent and family-owned company headquartered in Germany our full-service customized solutions range from supporting drug candidate selection by our TurboCell platform, as well as cell ... more

    Dr. Rentschler Holding GmbH & Co. KG

    Rentschler has been providing healthcare for over 75 years. In this time, the average lifespan in industrialized western countries has increased from 56 years in 1930 to 75 years in 2005 – as a result of the improved healthcare situation. Rentschler is helping to improve healthcare even fu ... more